Your session is about to expire
← Back to Search
Other
Experimental: 2.5% CBT-008 for Meibomian Gland Dysfunction
Phase 2
Waitlist Available
Research Sponsored by Cloudbreak Therapeutics, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
Study Summary
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical ophthalmic solution Control Treatment: CBT-008 vehicle
Eligible Conditions
- Meibomian Gland Dysfunction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of treatment-emergent adverse event
Secondary outcome measures
Ocular discomfort score (0-4)
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Experimental: 2.5% CBT-008Experimental Treatment1 Intervention
2.5% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
Group II: Experimental: 10% CBT-008Experimental Treatment1 Intervention
10% CBT-008 ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
Group III: Placebo Comparator: CBT-008Placebo Group1 Intervention
CBT-008 vehicle ophthalmic solution contains sodium phosphate monobasic monohydrate, sodium chloride, purified water, and sodium hydroxide to adjust pH to 7.4.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBT-008
2022
Completed Phase 2
~100
Find a Location
Who is running the clinical trial?
Cloudbreak Therapeutics, LLCLead Sponsor
5 Previous Clinical Trials
924 Total Patients Enrolled
1 Trials studying Meibomian Gland Dysfunction
90 Patients Enrolled for Meibomian Gland Dysfunction
Bing Leng, MDStudy DirectorADS Therapeutics, LLC
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger